Pertuzumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Pertuzumab and local guidelines before prescribing.
HER2 antibody
Mechanism
HER2 dimerisation inhibitor.
Uses
HER2-positive breast cancer (with trastuzumab).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Diarrhoea, cardiotoxicity, neutropenia, infusion reactions.
Interactions
Few.
Contraindications and cautions
Left ventricular dysfunction
Monitoring
LVEF
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
LVEF monitoring.
More from the textbook: uses, cautions and other points
- Trastuzumab / pertuzumab | HER2-positive breast cancer; echo monitoring (cardiotoxicity).
Oncology: Breast and Gynae Cancers - HER2 | Trastuzumab, pertuzumab | HER2-positive breast and gastric cancer (cardiotoxicity - echo monitoring)
Cell Biology: Cell cycle, signalling, cell death and stem cells - Trastuzumab (with pertuzumab in higher risk) for 1 year, with chemotherapy - often neoadjuvant .
Oncology: Breast and Gynae Cancers - Trastuzumab, pertuzumab and a taxane.
Oncology: Breast and Gynae Cancers
Where it is discussed in the book
- Oncology: Breast and Gynae Cancers (3 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)